Cencora, Inc.
Close on Oct 19, 2026
- Market cap
- $65.94B
- P/E (TTM)
- 25.2
- Dividend yield
- 0.65%
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $84.80B | $3.94 | $4.48 |
| Q2 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $78.40B | $8.40 | $4.75 |
| Q1 FY2026 Ended Dec 31, 2025 | Feb 4, 2026 | Before market open | $85.90B | $2.87 | $4.08 |
| Q4 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $83.70B | $-1.75 | $3.84 |
| Q3 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $80.70B | $3.52 | $4.00 |
| Q2 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $75.50B | $3.68 | $4.42 |
| Q1 FY2025 Ended Dec 31, 2024 | Feb 5, 2025 | Before market open | $81.50B | $2.50 | $3.73 |
| Q4 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $79.10B | $0.02 | $3.34 |
| Q3 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Dec 31, 2023 | Jan 31, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | 2026 | $900.00M | Maintained |
| Adjusted Diluted EPS Guidancenon-GAAP | Fiscal 2026 | $17.75 to $17.95 | Raised |
| Adjusted free cash flownon-GAAP | 2026 | $3.00B | Maintained |
| Adjusted operating incomenon-GAAP | 2026 | 13% to 14% growth | Raised |
| U.S. Healthcare Solutions Segmentnon-GAAP | 2026 | 14.5% to 15.5% growth | Raised |
| International Healthcare Solutions Segmentnon-GAAP | 2026 | 9% growth | Lowered |
| Othernon-GAAP | 2026 | 10% growth | Raised |
| Diluted weighted average shares outstanding | 2026 | 194 | Lowered |
| Adjusted effective tax ratenon-GAAP | 2026 | 20% | Maintained |
| Net interest expense | 2026 | $490.00M | Narrowed |
| Revenue | 2026 | 4% to 6% growth | Lowered |
| U.S. Healthcare Solutions Segment | 2026 | 4% to 6% growth | Maintained |
| International Healthcare Solutions Segment | 2026 | 8% growth | Raised |
| Other | 2026 | 6% growth | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Cencora filed with the SEC
ELECTS ROBERT E. SANCHEZ TO ITS BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2026 THIRD QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cencora Announces Samantha Hammock as Chief
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2026 SECOND QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CONSULTANTS OF AMERICA THROUGH ACQUISITION OF
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
of companion animal distribution, production animal distribution and technology platforms
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CENCORA CLOSES $3.0 BILLION SENIOR NOTES OFFERING
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CENCORA PRICES $500 MILLION 3.950% SENIOR NOTES
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
As used herein, the terms “Company,” “Cencora,” “we,” “us,” or “our” refer to Cencora, Inc., a Delaware corporation.
Other events · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2026 FIRST QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
COOPER TO ITS BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
raises long-term guidance expectations to reflect OneOncology’s expected long-term
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2025 FOURTH QUARTER AND FISCAL YEAR END RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
The following illustrates revised reportable segment revenue information for the periods indicated:
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.2 to Form 8-K
DURCAN AS CHAIRMAN OF ITS BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2025 THIRD QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
J. RYERKERK TO ITS BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2025 SECOND QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
COMMON SHARE REPURCHASE FROM WALGREENS BOOTS ALLIANCE
Material agreement · Other events · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2025 FIRST QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cencora Completes Acquisition of Retina Consultants
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA CLOSES $1.8 BILLION SENIOR NOTES OFFERING
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Leadership Through Acquisition of Retina Consultants of America
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2024 FOURTH QUARTER AND YEAR END RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CLYBURN TO ITS BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2024 THIRD QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
SHARE REPURCHASE FROM WALGREENS BOOTS ALLIANCE AND RAISES FISCAL 2024 GUIDANCE
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2024 SECOND QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Steven H. Collis to Transition to Executive Chair; COO Robert P. Mauch to Become President and CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA CLOSES $500 MILLION SENIOR NOTES OFFERING
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CENCORA PRICES $500 MILLION 5.125% SENIOR NOTES DUE 2034
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2024 FIRST QUARTER RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CENCORA REPORTS FISCAL 2023 FOURTH QUARTER AND YEAR END RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AmerisourceBergen becomes Cencora, in alignment
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
AMERISOURCEBERGEN ELECTS WERNER BAUMANN AND LAUREN TYLER TO ITS BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K